Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Higher-dose ocrelizumab versus approved-dose ocrelizumab in adults with primary progressive multiple sclerosis
2023-506515-18-00Phase 3Authorised
- Sponsor
- Roche
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial of ocrelizumab in primary progressive multiple sclerosis (PPMS) (2 arms), sponsored by Roche. Primary endpoint: Time to onset of cCDP sustained for at least 12 weeks. Planned start Feb 2024; status: authorised.
02
Drugs
ocrelizumab
03
Conditions
primary progressive multiple sclerosis (PPMS)
Beyond the preview
Go deeper on 2023-506515-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506515-18-00.